Bevacizumab in combination with first-line treatment for metastatic non-small cell lung cancer in clinical practice. Results of the EOLE study

Introduction. - The EOLE cohort aimed to describe, in routine clinical practice, the characteristics and management of patients receiving bevacizumab in combination with first-line metastatic chemotherapy for advanced metastatic or recurrent non squamous non-small cell lung cancer (nsNSCLC), as well as its efficacy and safety. Methods. - A total of 423 patients were enrolled in this prospective, national, multicenter study. Data were collected every 3 months over an 18-month period. Results. - Amongst the 407 patients analyzed (mean age 60 +/- 10 years, male 68%, ECOG-PS <= 1 88%, smokers or former smokers 87%, cardiovascular comorbidities 40%), all except for 2 patients received bevacizumab (7.5 or 15 mg/kg/3 weeks in 99% of patients) in combination with doublet chemotherapy. A total of 160 (60%) patients who completed induction received bevacizumab maintenance therapy. Median progression-free survival was 6.9 months (95% CI = [6.0-7.5]). Median overall survival (12.8 months [10.4-14.7]) was longer in patients with ECOG-PS <= 1 (14.4 months [12.3-15.9] versus 4.9 months [3.4-8.3] if ECOG-PS = 2). A total of 131 (32%) patients experienced at least one serious adverse event (SAE), and 51 (12%) at least one bevacizumab-related SAE. Conclusion. - EOLE confirms the efficacy and safety of bevacizumab in aNSCLC patients, in current medical practice. (C) 2016 SPLF. Published by Elsevier Masson SAS. All rights reserved.